Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | SHBG | P04278 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10404371 | 1.00 | CYP19A1 (0.51) | CYP19A1SHBGMAPK1POLBLMNA | |
| SCHEMBL27559513 | 1.00 | CYP19A1 (0.51) | CYP19A1SHBGMAPK1POLBLMNA | |
| SCHEMBL4996289 | 1.00 | CYP19A1 (0.51) | CYP19A1SHBGMAPK1POLBLMNA | |
| SCHEMBL10405242 | 0.86 | CYP19A1 (0.48) | CYP19A1SHBGMAPK1POLBLMNA | |
| SCHEMBL10405243 | 0.86 | CYP19A1 (0.48) | CYP19A1SHBGMAPK1POLBLMNA | |
| SCHEMBL31164338 | 0.86 | CYP19A1 (0.48) | CYP19A1SHBGMAPK1POLBLMNA | |
| SCHEMBL14677734 | 0.82 | SERPINA6 (0.50) | SHBGMAPK1POLBLMNAHSD17B10 | |
| SCHEMBL21807731 | 0.81 | CYP19A1 (0.54) | CYP19A1SHBGMAPK1POLBLMNA | |
| SCHEMBL10402803 | 0.81 | SHBG (0.60) | CYP19A1SHBGMAPK1POLBLMNA | |
| SCHEMBL497738 | 0.81 | CYP19A1 (0.54) | CYP19A1SHBGMAPK1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405207-B2 | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1033989-A4 | METHOD FOR REDUCING MAST CELL MEDIATED ALLERGIC REACTIONS | DOWELL TAD (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060217355-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating cancer | INFLABLOC PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060154908-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating depression | INFLABLOC PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-20060122160-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation | INFLABLOC PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006007312-A2 | CO-ADMINISTRATION OF DEHYDROEPIANDROSTERONE (DHEA) CONGENER WITH PHARMACEUTICALLY ACTIVE AGENTS FOR TREATING INFLAMMATION | INFLABLOC PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | INFLABLOC PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| EP-1011607-A4 | METHODS FOR PREVENTING PROGRESSIVE TISSUE NECROSIS, REPERFUSION INJURY, BACTERIAL TRANSLOCATION AND ADULT RESPIRATORY DISTRESS SYNDROME | UNIV UTAH RES FOUND (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040121991-A1 | Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers | INFLABLOC PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20040067920-A1 | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof | EPIGENESIS PHARMACEUTICALS LLC | 2004-04-08 | — | — | US | disclosed |
| US-6150348-A | ADMINISTERING A DEHYDROEPIANDROSTERONE (DHEA) DERIVATIVE TO A PATIENT SUFFERING FROM ADULT RESPIRATORY DISTRESS SYNDROME, PULMONARY HYPERTENSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1033989-A1 | METHOD FOR REDUCING MAST CELL MEDIATED ALLERGIC REACTIONS | University of Utah Research Foundation (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-1011607-A2 | METHODS FOR PREVENTING PROGRESSIVE TISSUE NECROSIS, REPERFUSION INJURY, BACTERIAL TRANSLOCATION AND ADULT RESPIRATORY DISTRESS SYNDROME | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-06-28 | — | — | EP | disclosed |
| US-5977095-A | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1999052532-A1 | METHOD FOR REDUCING CENTRAL NERVOUS SYSTEM IMPAIRMENT | PHARMADIGM, INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| US-5922701-A | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1999024039-A1 | METHOD FOR REDUCING MAST CELL MEDIATED ALLERGIC REACTIONS | PHARMADIGM, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5859000-A | ADMINISTERING DEHYDROEPIANDROSTERONE DERIVATIVE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998055074-A2 | METHODS FOR PREVENTING PROGRESSIVE TISSUE NECROSIS, REPERFUSION INJURY, BACTERIAL TRANSLOCATION AND ADULT RESPIRATORY DISTRESS SYNDROME | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1998-12-10 | — | — | WO | disclosed |
| US-4898694-A | 17-Hydroxy-steroids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121991-A1 | Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers | HSD17B11, SHBG, HSD3B1 | CYP19A1 30/4885SHBG 2/4885MAPK1 4496/4885 |
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | CYP17A1, CYP21A2, SHBG | CYP19A1 9/4885SHBG 3/4885MAPK1 4176/4885 |
| US-20060122160-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation | CYP17A1, CYP21A2, HSD17B7 | CYP19A1 14/4885SHBG 20/4885MAPK1 3658/4885 |
| US-20060217355-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating cancer | SHBG, CYP21A2, HSD17B11 | CYP19A1 4/4885SHBG 1/4885MAPK1 4816/4885 |
| US-20060154908-A1 | Co-administration of dehydroepiandrosterone (DHEA) congeners and other active agents for treating depression | SHBG, HSD17B11, HSD17B2 | CYP19A1 15/4885SHBG 1/4885MAPK1 4672/4885 |
| US-20040067920-A1 | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof | CYP17A1, HSD11B2, HSD17B7 | CYP19A1 38/4885SHBG 34/4885MAPK1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.